Anti-CLL-1 CAR NK cells Therapy(Shanghai General Hospital)

N/A

Report date: 2024/03/13 20:05:28

Base Information

Drug NameAnti-CLL-1 CAR NK cells Therapy(Shanghai General Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionC-Type lectin domain family 12 member A modulatorsNatural killer cell replacements

TargetsC-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesShanghai Jiao Tong University Affiliated First People'S Hospital

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Jiao Tong University Affiliated First People'S Hospital

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A